ALMDT Median Technologies

Median Technologies to Present at Cowen and Company 37th Annual Health Care Conference.

Regulatory News:

MEDIAN Technologies (Paris:ALMDT), the Imaging Phenomics™ Company, announced today that Fredrik Brag, Median’s Chief Executive Officer, will provide an overview of the Company and its strategic objectives at the Cowen and Company 37th Annual Health Care Conference.

The presentation will take place on Tuesday, March 7th at 08:40 am EST at the Marriott Copley Place in Boston, Massachusetts, USA.

About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics™ to provide insights into novel therapies and treatment strategies. Our unique solutions, LMS for lesion management and iBiopsy™ for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need, with an eye on reducing overall care costs. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a US subsidiary in Boston, Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA-PME SME equity savings plan setup and has received the label Pass French Tech Promotion 2016-2017. More information: www.mediantechnologies.com

EN
28/02/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Median Technologies

Median Technologies: 1 director

A director at Median Technologies bought 56,242 shares at 1.660EUR and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

Maria Vara
  • Maria Vara

Median Technologies: EUR23.5m capital raise extends runway into Q4 202...

Median Technologies successfully secured a capital raise via ABSA of EUR23.5m in total gross proceeds, priced at EUR1.66 (at ~18% discount to 20-day VWAP). The offering was oversubscribed, surpassing the initial EUR22m target, with 64% backed by existing shareholders, 2% by a public offering in Fra

Maria Vara
  • Maria Vara

Median Technologies: Launch of EUR22m capital increase to unlock EIB f...

Median Technologies has launched a EUR22m capital increase via a public offering of shares with warrants (ABSA), priced at EUR1.66 (at ~18% discount to 20-day VWAP), with 78% of the deal already secured via existing and new investors. The raise aimed to i) meet the drawing conditions of the Tranche

Maria Vara
  • Maria Vara

Median Technologies: EIB loan signed, tied to equity raise and debt re...

Friday post-market, Median announced the final sign of the EIB loan agreement of EUR37.5m, which has been structured in three tranches (EUR19m, EUR8.5m, EUR10m) and with several key conditions being set to access the first one. These include i) a capital increase of at least EUR16m (including issua

Maria Vara
  • Maria Vara

Median Technologies: CE mark filing keep eyonis on track, US launch be...

Yesterday post-market, Median announced that it has submitted the Class IIb CE marking filing for eyonis LCS, just a month after the FDA 510(k) submission, precisely sticking to the company's timeline guidance. Our confidence in a positive outcome remains high, as both submissions are underpinned b

ResearchPool Subscriptions

Get the most out of your insights

Get in touch